In glioblastoma, MSH6 mutations or loss of expression have been associated with tumor progression during TMZ treatment and ensuing TMZ resistance [12,13,64], but the role of MSH6 in clinical melanoma is less well characterized [65]. The gene discussed is MSH6; the disease is glioblastoma.